These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 35929611)

  • 1. The effect of intensity of conditioning regimen on the outcome of HSCT in children with sickle cell disease.
    Alsultan A; Abujoub R; Elbashir E; Essa MF
    Clin Transplant; 2022 Nov; 36(11):e14787. PubMed ID: 35929611
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic hematopoietic stem cell transplantation for acute leukemia patients: a single center experience.
    Goker H; Ozdemir E; Uz B; Buyukasik Y; Turgut M; Serefhanoglu S; Aksu S; Sayinalp N; Haznedaroglu IC; Tekin F; Karacan Y; Unal S; Eliacik E; Isik A; Ozcebe OI
    Transfus Apher Sci; 2013 Dec; 49(3):590-9. PubMed ID: 23981652
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of Myeloablative Versus Reduced-Intensity Conditioning Regimens for Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia: A Cohort Study.
    Çiftçiler R; Göker H; Demiroğlu H; Aladağ E; Aksu S; Haznedaroğlu İC; Sayınalp N; Özcebe O; Tekin F; Büyükaşık Y
    Turk J Haematol; 2019 May; 36(2):88-96. PubMed ID: 30717586
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alternative donor hematopoietic stem cell transplantation for sickle cell disease in Europe.
    Gluckman E; Cappelli B; Scigliuolo GM; De la Fuente J; Corbacioglu S
    Hematol Oncol Stem Cell Ther; 2020 Dec; 13(4):181-188. PubMed ID: 32201153
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of donor type and conditioning regimen intensity on allogeneic transplantation outcomes in patients with sickle cell disease: a retrospective multicentre, cohort study.
    Eapen M; Brazauskas R; Walters MC; Bernaudin F; Bo-Subait K; Fitzhugh CD; Hankins JS; Kanter J; Meerpohl JJ; Bolaños-Meade J; Panepinto JA; Rondelli D; Shenoy S; Williamson J; Woolford TL; Gluckman E; Wagner JE; Tisdale JF
    Lancet Haematol; 2019 Nov; 6(11):e585-e596. PubMed ID: 31495699
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Poor outcome with nonmyeloablative conditioning regimen before cord blood transplantation for patients with high-risk acute myeloid leukemia compared with matched related or unrelated donor transplantation.
    Devillier R; Harbi S; Fürst S; Crocchiolo R; El-Cheikh J; Castagna L; Etienne A; Calmels B; Lemarie C; Prebet T; Granata A; Charbonnier A; Rey J; Chabannon C; Faucher C; Vey N; Blaise D
    Biol Blood Marrow Transplant; 2014 Oct; 20(10):1560-5. PubMed ID: 24933658
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of allogeneic hematopoietic stem cell transplantation for chronic granulomatous disease in children: A multicentre, retrospective cohort study in China.
    Si Y; Dou Y; Zhai X; Zhou C; Lu W; Meng Y; Qian X; Chen J; Wang P; Luo C; Yu J; Tang X
    Clin Immunol; 2024 Mar; 260():109919. PubMed ID: 38309448
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Post-Transplantation Cyclophosphamide-Based Haploidentical versus Matched Unrelated Donor Peripheral Blood Hematopoietic Stem Cell Transplantation Using Myeloablative Targeted Busulfan-Based Conditioning for Pediatric Acute Leukemia.
    Hong KT; Park HJ; Kim BK; An HY; Choi JY; Kang HJ
    Transplant Cell Ther; 2022 Apr; 28(4):195.e1-195.e7. PubMed ID: 35021131
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treosulfan-based conditioning regimen for allogeneic haematopoietic stem cell transplantation in children with sickle cell disease.
    Strocchio L; Zecca M; Comoli P; Mina T; Giorgiani G; Giraldi E; Vinti L; Merli P; Regazzi M; Locatelli F
    Br J Haematol; 2015 Jun; 169(5):726-36. PubMed ID: 25818248
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of matched unrelated donors compared with matched related donors is associated with lower relapse and superior progression-free survival after reduced-intensity conditioning hematopoietic stem cell transplantation.
    Ho VT; Kim HT; Aldridge J; Liney D; Kao G; Armand P; Koreth J; Cutler C; Ritz J; Antin JH; Soiffer RJ; Alyea EP
    Biol Blood Marrow Transplant; 2011 Aug; 17(8):1196-204. PubMed ID: 21193054
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparable outcomes among unmanipulated haploidentical, matched unrelated, and matched sibling donors in BU-based myeloablative hematopoietic stem cell transplantation for intermediate and adverse risk acute myeloid leukemia in complete remission: a single-center study.
    Lu Y; Zhao YL; Zhang JP; Xiong M; Cao XY; Liu DY; Sun RJ; Wei ZJ; Zhou JR; Lu DP
    Ann Hematol; 2021 Jun; 100(6):1579-1591. PubMed ID: 33236196
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduced toxicity, myeloablative HLA-haploidentical hematopoietic stem cell transplantation with post-transplantation cyclophosphamide for sickle cell disease.
    Wiebking V; Hütker S; Schmid I; Immler S; Feuchtinger T; Albert MH
    Ann Hematol; 2017 Aug; 96(8):1373-1377. PubMed ID: 28573314
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Unrelated Umbilical Cord Blood Transplantation for Sickle Cell Disease Following Reduced-Intensity Conditioning: Results of a Phase I Trial.
    Abraham A; Cluster A; Jacobsohn D; Delgado D; Hulbert ML; Kukadiya D; Murray L; Shenoy S
    Biol Blood Marrow Transplant; 2017 Sep; 23(9):1587-1592. PubMed ID: 28578010
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Matched sibling donor stem cell transplantation for sickle cell disease: Results from the Spanish group for bone marrow transplantation in children.
    Benítez-Carabante MI; Beléndez C; González-Vicent M; Alonso L; Uría-Oficialdegui ML; Torrent M; Pérez-Hurtado JM; Fuster JL; Cela E; Díaz-de-Heredia C;
    Eur J Haematol; 2021 Mar; 106(3):408-416. PubMed ID: 33296531
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Bortezomib-Based Regimen Offers Promising Survival and Graft-versus-Host Disease Prophylaxis in Myeloablative HLA-Mismatched and Unrelated Donor Transplantation: A Phase II Trial.
    Koreth J; Kim HT; Lange PB; Bindra B; Reynolds CG; Chammas MJ; Armand P; Cutler CS; Ho VT; Glotzbecker B; Nikiforow S; Ritz J; Blazar BR; Soiffer RJ; Antin JH; Alyea EP
    Biol Blood Marrow Transplant; 2015 Nov; 21(11):1907-13. PubMed ID: 26055298
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of Myeloablative versus Reduced-Intensity Conditioning Regimens in Allogeneic Stem Cell Transplantation Recipients with Acute Myelogenous Leukemia with Measurable Residual Disease-Negative Disease at the Time of Transplantation: A Retrospective Cohort Study.
    Yu J; Du Y; Ahmad S; Patel RD; Varela JC; Chang CC; Mori S
    Transplant Cell Ther; 2021 Aug; 27(8):663.e1-663.e6. PubMed ID: 33951497
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The long-term outcome of reduced-intensity allogeneic stem cell transplantation from a matched related or unrelated donor, or haploidentical family donor in patients with leukemia: a retrospective analysis of data from the China RIC Cooperative Group.
    Yu CL; Zheng-Dong ; Qiao ZH; Wang JM; Huang-He ; Liang YM; Wu DP; Chen BA; Bai-Hai ; Shi BF; Sun WJ; Qiao JX; Guo M; Qiao JH; Sun QY; Hu KX; Huang YJ; Zuo HL; Huang XJ; Ai HS
    Ann Hematol; 2017 Feb; 96(2):279-288. PubMed ID: 27864604
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduced-intensity conditioning is effective for hematopoietic stem cell transplantation in young pediatric patients with Diamond-Blackfan anemia.
    Koyamaishi S; Kamio T; Kobayashi A; Sato T; Kudo K; Sasaki S; Kanezaki R; Hasegawa D; Muramatsu H; Takahashi Y; Sasahara Y; Hiramatsu H; Kakuda H; Tanaka M; Ishimura M; Nishi M; Ishiguro A; Yabe H; Sarashina T; Yamamoto M; Yuza Y; Hyakuna N; Yoshida K; Kanno H; Ohga S; Ohara A; Kojima S; Miyano S; Ogawa S; Toki T; Terui K; Ito E
    Bone Marrow Transplant; 2021 May; 56(5):1013-1020. PubMed ID: 32948829
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Measurable residual disease, conditioning regimen intensity, and age predict outcome of allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first remission: A registry analysis of 2292 patients by the Acute Leukemia Working Party European Society of Blood and Marrow Transplantation.
    Gilleece MH; Labopin M; Yakoub-Agha I; Volin L; Socié G; Ljungman P; Huynh A; Deconinck E; Wu D; Bourhis JH; Cahn JY; Polge E; Mohty M; Savani BN; Nagler A
    Am J Hematol; 2018 Sep; 93(9):1142-1152. PubMed ID: 29981272
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Allogeneic hematopoietic stem cell transplantation in Philadelphia-negative adult ALL: myeloablative, non-myeloablative, and beyond.
    Hwang YY; Mohty M; Chim CS
    Hematology; 2015 Mar; 20(2):61-71. PubMed ID: 24993587
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.